Ionis Pharmaceuticals Inc
Research Ionis Pharmaceuticals Inc (IONS) on Bullrun: market cap USD 13.34B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIONS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 13.34B
- Financial periodFY2025
- RevenueUSD 943.71M
- Revenue growth33.8%
- Net income-USD 381.39M
- Free cash flow-USD 320.03M
- Gross margin98.3%
Valuation Snapshot
latest market cap is USD 13.34B.
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults;
Frequently asked questions
What is Ionis Pharmaceuticals Inc's market cap?
Ionis Pharmaceuticals Inc's market capitalization is USD 13.34B.
What does Ionis Pharmaceuticals Inc do?
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis;